Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011.
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candidemia is common and associated with high morbidity and mortality; changes in population-based incidence rates have not been reported. METHODS: We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, and Baltimore City/County, Maryland (combined population 5.2 million), during 2008-2011. We calculated candidemia incidence and antifungal drug resistance compared with prior surveillance (Atlanta, 1992-1993; Baltimore, 1998-2000). RESULTS: We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 in Baltimore. Rates were highest among adults aged ≥65 years (Atlanta, 59.1; Baltimore, 72.4) and infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior surveillance, adjusted incidence significantly declined for infants of both black and white race (Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17-.38]; white RR: 0.19 [95% CI, .12-.29]; Baltimore: black RR, 0.38 [95% CI, .22-.64]; white RR: 0.51 [95% CI: .29-.90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluconazole and an echinocandin. CONCLUSIONS: We describe marked shifts in candidemia epidemiology over the past 2 decades. Adults aged ≥65 years replaced infants as the highest incidence group; adjusted incidence has declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, or changes in catheter insertion practices may be contributing to these declines. Further surveillance for antifungal resistance and efforts to determine effective prevention strategies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All-cause in-hospital mortality of candidemia has been reported as high as 36% in the US.27,51,52”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [51]
In the citing paper
“Candidemia is one of the most common health care–associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“In population-based surveillance performed in the metropolitan areas of Atlanta, Georgia, and Baltimore, Maryland, candidemia incidence (primarily among adults) increased 10%–40% from the early 1990s and the late 2000s, which was followed by more recent reports of decreases in these areas (6,28–30).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“This contrasts with data from the early 1990s, when infants had the highest incidence (6), followed by substantial decreases by the late 2000s (26,28).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“The previously reported racial disparity in candidemia persisted in this surveillance period (6), with a 2.3 times higher incidence among blacks than among nonblacks.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198 · cited 1×
“%) met criteria for sepsis [19].”
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
Pronovost, P., Needham, D., Berenholtz, S., Sinopoli, D., Chu, H., Cosgrove, S., Sexton, B., Hyzy, R., Welsh, R., Roth, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061115 · Cited by 4,387 · cited 2×
“…dramatic declines in some central line– associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus , following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida species [20, 24, 34–36].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“shown to decrease risk of disease [21, 25–29].”
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · cited 1×
“Increases in common risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving immunosuppressive therapies [33] may have resulted in increases in the overall pool of patients at high risk for candidemia.”
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“0 %) between centres [2, 14, 18, 31] possibly because of lack of standardized criteria.”
Research works printed but not linked: 2
- 1992, Chest, 10, 1644
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
Cited by
Items 201–300 of 411
Roohani, A. H., Fatima, N., Shameem, M., Khan, H. M., Khan, P. A., & Akhtar, A. (2018) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_18_258 · Cited by 20
“The (crude) mortality amongst people with candidemia is approximately 30%.[50] Our study showed 24.”
BackgroundEpidemiology and risk factors of candidemia due to Candida parapsilosis in an intensive care unit
Zuo, X., Liu, Y., & Hu, K. (2021) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202163020 · Cited by 20
Marquez, L., Lee, Y., Duncan, D., Whitesell, L. J., Cowen, L. E., & Quave, C. L. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00113 · Cited by 19
A Risk Score for Fluconazole Failure among Patients with Candidemia
Ostrosky-Zeichner, L. L., Harrington, R. L., Azie, N. E., Yang, H., Li, N., Zhao, J., Koo, V., & Wu, E. Q. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02091-16 · Cited by 19
Antifungal Drugs in Newborns and Children
Puia‐Dumitrescu, M., & Smith, P. B. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.08.013 · Cited by 19
Bretagne, S., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Che, D., Dromer, F., & YEASTS, P. O. T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641965 · Cited by 19
Vallabhaneni, S., Almendares, O. M., Farley, M. M., Reno, J., Smith, Z. R., Stein, B., Magill, S. S., Smith, R. M., Cleveland, A. A., & Lessa, F. C. (2015) · Epidemiology and Infection · doi:10.1017/s0950268815003027 · Cited by 19
Self-citationUllah, N., Muccio, M., Magnasco, L., Sepulcri, C., Giacobbe, D. R., Vena, A., Bassetti, M., & Mikulska, M. (2025) · Journal of Fungi · doi:10.3390/jof11020149 · Cited by 18
Cost Analysis of Fluconazole Prophylaxis for Prevention of Neonatal Invasive Candidiasis
Swanson, J. R., Vergales, J., Kaufman, D. A., & Sinkin, R. A. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001068 · Cited by 18
Sinh, C. T., Loi, C. B., Minh, N. T., Lam, N. N., Quang, D. X., Đỗ, Q., Ánh, Đ. N., Hien, T. T. T., Su, H. X., & Le, T. (2021) · Mycopathologia · doi:10.1007/s11046-021-00569-7 · Cited by 17
Stoia, D., Sio, L. D., Petronella, F., & Focşan, M. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116243 · Cited by 17
“Candidaemia , a Candida infection of the blood, owns a rate of 2 – 26 infections per 100000 people (Arendrup, 2010; Cleveland et al., 2012; Puig-Asensio et al., 2014), with a mortality rate between 30 and 55% (Brown et al., 2012).”
Srisurapanont, K., Lerttiendamrong, B., Meejun, T., Thanakitcharu, J., Manothummetha, K., Thongkam, A., Chuleerarux, N., Sanguankeo, A., Li, L. X., Leksuwankun, S., et al. (2024) · Mycoses · doi:10.1111/myc.13798 · Cited by 17
Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms
Dominguez, E. G., & Andes, D. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_6 · Cited by 17
The phosphatome of opportunistic pathogen Candida species
Szabó, K., Miskei, M., Farkas, I., & Dombrádi, V. (2021) · Fungal Biology Reviews · doi:10.1016/j.fbr.2020.12.002 · Cited by 17
Taj‐Aldeen, S. J., Salah, H., Perez, W. B., Almaslamani, M., Motyl, M. R., AbdulWahab, A., Healey, K. R., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00214-18 · Cited by 17
“9) 5 Clavispora (Candida) lusitaniae 6 (2) 6 Candida orthopsilosis 4 (1.”
BackgroundClinical and Microbiological Investigation of Fungemia from Four Hospitals in China
Dong, D., Li, Z., Zhang, L., Jiang, C., Mao, E., Wang, X., & Peng, Y. (2015) · Mycopathologia · doi:10.1007/s11046-014-9855-0 · Cited by 17
Why Candida Sepsis Should Matter to ICU Physicians
Skrobik, Y. K., & Laverdière, M. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.06.007 · Cited by 16
Evolution and Application of Inteins in Candida species: A Review
Fernandes, J. A. L., Prandini, T. H. R., Castro, M. D. C. A., Arantes, T. D., Giacobino, J., Bagagli, E., & Theodoro, R. C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01585 · Cited by 16
“The applications of this technology are numerous for different social-economic fields, such as gene therapy for monogenic diseases, insect vector control (already developed for malaria mosquitoes) and gene delivery for transgenic plants, such as maize (Belfort and Bonocora, 2014).”
BackgroundKumar, Y., Wani, F. A., Ahmedi, S., Shamsi, A., Nadeem, M., Manzoor, N., Kamli, M. R., Malik, M. A., Rizvi, M. M. A., & Patel, R. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124631 · Cited by 16
Stojanović, P., Stojanović, N. M., Stojanović-Radić, Z. Z., Arsić-Arsenijević, V. S., Otašević, S., Randjelović, P. J., & Radulović, N. S. (2016) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.7970 · Cited by 16
on behalf of GISA/FADOI Candida Study Group, Sozio, E., Pieralli, F., Azzini, A. M., Tintori, G., Demma, F., Furneri, G., Sbrana, F., Bertolino, G., Fortunato, S., et al. (2018) · Infection · doi:10.1007/s15010-018-1162-0 · Cited by 16
Can host receptors for fungi be targeted for treatment of fungal infections?
Filler, S. G. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.05.006 · Cited by 16
Li, X., Sholeh, M., Moghadam, M. A., Ostadrahimi, M., & Hosseini, S. S. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12653-8 · Cited by 15
Carvalho, C., Yang, J., Vogan, A. A., Maganti, H. B., Yamamura, D. L. R., & Xu, J. (2013) · Mycoses · doi:10.1111/myc.12156 · Cited by 15
A Candida parapsilosis Overexpression Collection Reveals Genes Required for Pathogenesis
Pál, S. E., Tóth, R., Nosanchuk, J. D., Vágvölgyi, C., Németh, T., & Gácser, A. (2021) · Journal of Fungi · doi:10.3390/jof7020097 · Cited by 15
Exploiting new knowledge of Candidal infection for future antifungal combat
Kragelund, C. (2016) · Oral Diseases · doi:10.1111/odi.12546 · Cited by 15
Vallabhaneni, S., Sapiano, M., Weiner, L. M., Lockhart, S. R., & Magill, S. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx175 · Cited by 14
“Candida albicans, which accounted for the majority of invasive Candida infections in the past, now causes <40% of invasive Candida infections, while more drug-resistant species, such as Candida glabrata, account for one-third of all invasive Candida infections [2].”
BackgroundSelf-citationAhn, H., Lee, R., Cho, S., & Lee, D. (2022) · Blood Research · doi:10.5045/br.2022.2022036 · Cited by 14
“C. glabrata was the most common species among non-albicans species in Korea, similar in the United States [16-19].”
BackgroundZeng, G., Xu, X., Kok, Y. J., Deng, F.-S., Chow, E. W. L., Gao, J., Bi, X., & Wang, Y. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113473 · Cited by 14
Filler, E. E., Liu, Y., Solis, N. V., Wang, L., Diaz, L. F., Edwards, J. E., Filler, S. G., & Yeaman, M. R. (2021) · Infection and Immunity · doi:10.1128/iai.00146-20 · Cited by 13
“In the United States, Candida glabrata causes approximately one third of cases of hematogenously disseminated candidiasis (1, 2).”
BackgroundAmann, V., Kissmann, A., Mildenberger, V., Krebs, I., Perez‐Erviti, J. A., Martell-Huguet, E. M., Otero‐González, A. J., Morales-Vicente, F., Rodríguez-Castaño, G. P., Firacative, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129788 · Cited by 13
Regulatory role of Mss11 in Candida glabrata virulence: adhesion and biofilm formation
Wang, L.-L., Huang, S., Zhao, J., Liu, J., & Xiang, M.-J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1321094 · Cited by 13
Solomon, D. A., Nyerere, A. K., Kanyua, A., & Ngugi, C. W. (2021) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2021.111003 · Cited by 14
“In spite of certain reports expressing Candida parapsilosis as frequently susceptible to azoles [38] [39], several pieces of research have indicated its increased resistance towards Fluconazole [23] [40] [41].”
ResultInvasive Fungal Infections and Approaches to Their Diagnosis
Pfaller, M. A. (2015) · Methods in microbiology · doi:10.1016/bs.mim.2015.05.002 · Cited by 13
Silva, M. G. C., Rodrigues, G. S., Gonçalves, I. L., & Grazziotin, N. A. (2015) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.5935/1676-2444.20150027 · Cited by 13
“And as the number of reports about the antifungal-resistant Candida species has been increasing((6-9)), the early establishment of an adequate treatment of candidemia is associated with a favorable prognosis((10)).”
BackgroundAl‐Dorzi, H. M., & Arabi, Y. M. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000387 · Cited by 13
Use of T2MR in Invasive Candidiasis with and Without Candidemia
Zacharioudakis, I. M., Zervou, F. N., & Mylonakis, E. E. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0079 · Cited by 13
Candida lusitaniae MICs to the echinocandins are elevated but FKS -mediated resistance is rare
Lockhart, S. R., Pham, C. D., Kuykendall, R. J., Bolden, C. B., & Cleveland, A. A. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.08.012 · Cited by 12
Self-citationDong, S., Shi, H., Cao, D., Wang, Y., Zhang, X., Li, Y., Gao, X., & Wang, L. (2016) · Scientific Reports · doi:10.1038/srep32256 · Cited by 12
Prevention of hospital pathogen biofilm formation by antimicrobial peptide KWI18
Lima, L. S., Ramalho, S. R., Sandim, G. C., Parisotto, E. B., Sardi, J. D. C. O., & Macedo, M. L. R. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105791 · Cited by 12
Candidemia in the pediatric intensive care unit in Eastern India
Mishra, R., Behera, C. K., Jena, P., Mishra, S. N., Sahoo, B., Patnaik, S., & Jain, M. K. (2020) · JOURNAL OF PEDIATRIC CRITICAL CARE · doi:10.4103/jpcc.jpcc_38_20 · Cited by 12
Epidemiología de candidemia en Córdoba. Estudio de vigilancia de cinco instituciones
Riera, F. O., Medeot, M., Sartori, L., Bergallo, C., Minoli, J., Vilchez, V., Sánchez, P., Abiega, C., Pincheira, C., Correa, S., et al. (2014) · Revista de la Facultad de Ciencias Médicas de Córdoba · doi:10.31053/1853.0605.v71.n2.9074 · Cited by 11
The SAGA and NuA4 component Tra1 regulates Candida albicans drug resistance and pathogenesis
Razzaq, I., Berg, M. D., Jiang, Y., Genereaux, J. L., Uthayakumar, D., Kim, G. H., Agyare-Tabbi, M. R., Halder, V., Brandl, C. J., Lajoie, P., et al. (2021) · Genetics · doi:10.1093/genetics/iyab131 · Cited by 11
Serum bridging molecules drive candidal invasion of human but not mouse endothelial cells
Phan, Q. T., Solis, N. V., Lin, J., Swidergall, M., Singh, S., Liu, H., Sheppard, D. C., Ibrahim, A. S., Mitchell, A. P., & Filler, S. G. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010681 · Cited by 11
“By contrast, these organisms are still able to cross the endothelial cell lining of the vasculature in humans and infect target organs during disseminated infection [2,3].”
A Review of Studies on Candida Species in Peninsular Malaysia
Farooq, H., Monowar, T., Latt, S. S., Chinni, S. V., Zainol, N. H., & Sabesan, G. S. (2022) · Advanced Biomedical Research · doi:10.4103/abr.abr_3_22 · Cited by 11
“glabrata rose two‐and‐four‐fold, respectively, between those years, indicating a rise in the prevalence of those two species in that region.[8] Similarly, various other prevalence studies from different institutions, cities, countries, and broad geographic regions have reported the emergence of various non‐albicans Ca…”
BackgroundNaicker, S. D., Shuping, L., Zulu, T. G., Mpembe, R. S., Mhlanga, M., Tsotetsi, E., Maphanga, T. G., Govender, N. P., MMed, F. P. S., Black, J., et al. (2023) · Medical Mycology · doi:10.1093/mmy/myad057 · Cited by 11
Old and new: appropriate dosing for neonatal antifungal drugs in the nursery
Ericson, J. E., Manzoni, P., & Benjamin, D. K. (2013) · Early Human Development · doi:10.1016/s0378-3782(13)70009-4 · Cited by 11
“Resistance to fluconazole appears to be increasing; some centers report fluconazole resistance among Candida isolates as high as 8%, mostly among non-albicans species (7).”
BackgroundMechanisms of Drug Resistance in Candida albicans
Sanglard, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_15 · Cited by 11
Lausch, K. R., Søgaard, M., Rosenvinge, F. S., Johansen, H. K., Boysen, T., Røder, B. L., Mortensen, K. L., Nielsen, L. B., Lemming, L. E., Olesen, B. R. S., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s176384 · Cited by 11
“3%) is comparable with other studies that report using echinocandins as primary treatment in 17%–57% of patients with candidemia.(16,18,22,23,28) We are unaware of prior nationwide studies on the compliance with treatment recommendations.”
ResultEstimated Incidence and Prevalence of Serious Fungal Infections in Morocco
Lmimouni, B., Hennequin, C., Penney, R. O. S., & Denning, D. W. (2022) · Journal of Fungi · doi:10.3390/jof8040414 · Cited by 11
“We have assumed a conservative annual incidence of 5/100,000, which converts to about 1800 cases [52,53].”
BackgroundYang, Q., Liu, Z., Wang, Y., Xie, J., Zhang, K., Wang, Y. F., & Wang, Y. F. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.056 · Cited by 11
Obeng, J., Agyei-Dwarko, D., Teinor, P., Danso, I., Lutuf, H., Lekete-Lawson, E., Ablormeti, F. K., & Eddy-Doh, M. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-27972-y · Cited by 11
Liu, S. H., Mitchell, H., & Al‐Rawahi, G. N. (2023) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0021 · Cited by 11
Reduced susceptibility to fluconazole in a cat with histoplasmosis
Renschler, J. S., Norsworthy, G. D., Rakian, R., Rakian, A., Wheat, L. J., & Hanzlicek, A. S. (2017) · Journal of Feline Medicine and Surgery Open Reports · doi:10.1177/2055116917743364 · Cited by 11
Gradel, K. O., Nielsen, S. L., Pedersen, C., Knudsen, J. D., Østergaard, C., Arpi, M., Jensen, T. G., Kolmos, H. J., Schønheyder, H. C., Søgaard, M., et al. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/678593 · Cited by 11
Lee, Y., Chen, Y., Wang, J., Wang, F., Hsieh, M.-H., Hii, I.-M., Lee, Y.-L., Ho, M., Liu, C.-E., Chen, Y., et al. (2021) · Nutrients · doi:10.3390/nu13093218 · Cited by 10
Rapid preparation of Candida genomic DNA: combined use of enzymatic digestion and thermal disruption
He, Z., Huo, X., & Piao, J. (2023) · AMB Express · doi:10.1186/s13568-022-01500-z · Cited by 10
Kahramanmaras Afsin Devlet Hastanesi, I. H. V. K. M. K., Kolak, C. C., Daloğlu, A. E., Özhak, B., Öğünç, D., & Günseren, F. (2020) · Klimik Dergisi/Klimik Journal · doi:10.5152/kd.2019.71 · Cited by 10
Rauseo, A. M., Olsen, M. A. A., Stwalley, D. L., Mazi, P. B., Larson, L., Powderly, W. G., & Spec, A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac447 · Cited by 10
On behalf of the French Mycoses Study Group, Desnos‐Ollivier, M., Uruguayan Invasive Fungal Infection Network, Bórmida, V., Poirier, P., Nourrisson, C., Pan, D., Bretagne, S., Puime, A., & Dromer, F. (2017) · Mycopathologia · doi:10.1007/s11046-017-0224-7 · Cited by 10
“For C. parapsilosis resistance to fluconazole is more frequently noticed [3.6% in the ARTEMIS program [26]; 2–6% in population-based surveillance by the Centers for Disease Control [27]] than resistance to voriconazole [\ 2% in the ARTEMIS program [26]; 0% in Americas, in Europe and only 1.1% in Asia in the SENTRY Sur…”
BackgroundInfluentialClinical predictive models of invasive Candida infection: A systematic literature review
Rauseo, A. M., Aljorayid, A., Olsen, M. A. A., Larson, L., Lipsey, K. L., Powderly, W. G., & Spec, A. (2021) · Medical Mycology · doi:10.1093/mmy/myab043 · Cited by 9
Wu, Z., Wu, Q., Yuan, W., Chen, Y., Hu, D., Deng, D., Zhang, L.-L., & Niu, X. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04051-22 · Cited by 9
Żarnowski, R., Jaromin, A., Zagórska, A., Dominguez, E. G., Sidoryk, K., Gubernator, J., & Andes, D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010108 · Cited by 9
“Even though device removal is recommended for patients with Candida-infected medical devices, removal of these gadgets presents a serious, often deadly risk to critically ill individuals [10].”
BackgroundElhasan, L. M. E., Hassan, M. B., Elhassan, R. M., Abdelrhman, F. A., Salih, E. A., Asma Ibrahim., H., Mohamed, A. A., Osman, H. S., Khalil, M. S. M., Alsafi, A. A., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/8280925 · Cited by 9
Gao, Y., Tang, M., Li, Y., Niu, X., Li, J., Fu, C., Wang, Z., Liu, J., Song, B., Chen, H., et al. (2022) · PeerJ · doi:10.7717/peerj.13594 · Cited by 9
“The mortality rate of candidemia was 29% according to a population-based study from the USA, 31% according to a study from Spain, 54% according to a multi-centre study from Brazil and 60% according to a survey conducted in South Africa (Colombo et al., 2006; Cleveland et al., 2012; Kreusch & Karstaedt, 2013; Puig-Asen…”
Thomson, K. S., Thomson, G. K., Biehle, J., Deeb, A., Crawford, J., & Herrera, R. (2016) · Current Therapeutic Research · doi:10.1016/j.curtheres.2016.07.001 · Cited by 9
Introductory Chapter: Epidemiology of Invasive Fungal Infection - An Overview
Loreto, É. S., & Tondolo, J. S. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85955 · Cited by 9
John, C. N., Abrantes, P. M. D. S., Prusty, B. K., Ablashi, D. V., & Africa, C. W. J. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01021 · Cited by 10
Zambom, C. R., da Fonseca, F. H., & Garrido, S. S. (2020) · Microorganisms · doi:10.3390/microorganisms8071024 · Cited by 9
Influence of Abiotic Factors in the Emergence of Antibiotic Resistance
Dutta, S., & Ramamurthy, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-3658-8_4 · Cited by 9
Zeng, G., Xu, X., Gao, J., Dantas, A. D. S., Gow, N. A. R., & Wang, Y. (2021) · The Cell Surface · doi:10.1016/j.tcsw.2021.100057 · Cited by 9
“albicans is the leading cause of hospital-acquired bloodstream infections in immunocompromised patients with high morbidity and mortality rates (Cleveland et al., 2012).”
BackgroundSequence-identification of Candida species isolated from candidemia
Fathi, N., Mohammadi, R., Tabatabaiefar, M. A., Ghahri, M., & Sadrossadati, S. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.188485 · Cited by 9
“Cleveland et al.[18] revealed 61% of patients were in an ICU within the 14 days before or after candidemia.”
BackgroundVendetti, N., Bryan, M. W., Zaoutis, T. E., Damianos, A., & Fisher, B. T. (2015) · Mycoses · doi:10.1111/myc.12449 · Cited by 9
Epidemiology of candidemia at a tertiary Canadian hospital, 2004–2013
Remington, T. L., Isaac, A., Vickers, D., Fuller, J., & Smith, S. W. (2018) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi.3.1.04 · Cited by 8
Emerging trends of invasive yeast infections and azole resistance in Beijing intensive care units
Yu, J., Yang, W., Fan, X., Cui, E., Min, R., Yuan, H., Hu, Y., Wang, H., Zhang, G., Zhao, Y. Y., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.04.020 · Cited by 8
Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
Suh, J. W., Kim, S. B., Yoon, Y. K., Sohn, J. W., Kim, M. J., & Kim, J. H. (2020) · Mycopathologia · doi:10.1007/s11046-020-00471-8 · Cited by 8
Vitale, R. G., & Nucci, M. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0164-8 · Cited by 8
Puesta al día en la candidiasis invasora en el paciente crítico no neutropénico
Zaragoza, R., Ramírez, P., Borges-Sa, M., & Pemán, J. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.03.001 · Cited by 8
Wu, Y., Wei, D., Gong, X., Shen, Y., Zhu, Y., Wang, J., & Gao, Z. (2020) · Translational Pediatrics · doi:10.21037/tp-20-37 · Cited by 8
“Transl Pediatr 2020;9(4):480-486 | http://dx.”
Wiwing, V., Suryadinata, N., & Lumbuun, N. (2024) · PubMed Central · doi:10.21010/ajidv18n2s.2 · Cited by 7
Multidrug- and Cross-Resistant Candida: the Looming Threat
Lackner, M., Martín‐Vicente, A., & Lass‐Flörl, C. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0210-1 · Cited by 7
de Oliveira, M. T., Batista, N. K. R., Gil, E. D. S., Silva, M. D. R. R., Costa, C. R., Bara, M. T. F., & Torres, I. M. S. (2020) · Medical Mycology · doi:10.1093/mmy/myaa004 · Cited by 7
Yardımcı, A. C., & Arman, D. (2022) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.120801 · Cited by 7
Raj, R., Hendrie, J. D., Jacob, A., & Adams, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00020 · Cited by 7
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 7
Hazırolan, G. (2018) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2018.038 · Cited by 6
Membrane et paroi fongiques : des rôles clés dans la résistance aux antifongiques
Garnaud, C., & Cornet, M. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30062-9 · Cited by 6
Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia
Miranti, E., Ho, D. Y., Enriquez, K. T., Subramanian, A. K., Medeiros, B. C., & Epstein, D. J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2060504 · Cited by 6
“Candida infections, with longitudinal studies reporting increasing incidence of non-albicans Candida species over time [20,21].”
BackgroundNathiya, D., Karthika, V., Wilson, J., Arumugam, A., & Gurunathan, K. (2021) · IET Nanobiotechnology · doi:10.1049/nbt2.12055 · Cited by 6
Yenişehirli, G., Özveren, G., Yenişehirli, A., & Bulut, Y. (2018) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.59404 · Cited by 6
Tsay, S. V., Williams, S. R., Benedict, K., Beldavs, Z. G., Farley, M. M., Harrison, L. H., Schaffner, W., Dumyati, G. K., Blackstock, A. J., Guh, A. Y., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy607 · Cited by 6
Self-citationKaruga, F. F., Góralska, K., & Brzeziańska‐Lasota, E. (2021) · Acta Mycologica · doi:10.5586/am.566 · Cited by 6
Investigation of Candida species isolated from blood cultures
Atik, T. K., & Duran, A. Ç. (2021) · Van Medical Journal · doi:10.5505/vtd.2021.73383 · Cited by 6
“glabrata'ya bağlı kandidemi insidansının, 1992-1993 ve 2008-2011 yılları arasında sırasıyla iki ve dört kat arttığı görülmüştür (9).”
Vahedi‐Shahandashti, R., Moroder, E., & Lass‐Flörl, C. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-25 · Cited by 5
Theodore, D., Henneman, A. D., Loo, A. S., Shields, R. K., Eschenauer, G. A., Sobieszczyk, M. E., & Kubin, C. J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae175 · Cited by 5
Fungal Infections in People Who Use Drugs
Gonzales, J. P., & Ostrosky-Zeichner, L. L. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf107 · Cited by 5
“Fluconazole resistance rates have been reported at 11%–13% for N glabrata , 2%–6% of C parapsilosis , and 4%–9% of C tropicalis isolate [29, 30].”
Emerging fungal pathogens in solid organ transplantation
Mishkin, A. D. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000889 · Cited by 5
Klebsiella pneumoniae Infections in Intensive Care Unit and Risk Factors for Carbapenem Resistance
Yeşilbağ, Z., Şeker, Y. T., Şenoğlu, S., & Hergünsel, G. O. (2021) · Klimik Dergisi/Klimik Journal · doi:10.36519/kd.2021.05 · Cited by 5
Management of invasive fungal infections in the pediatric intensive care unit
Fisher, B. T., Zaoutis, T. E., & Chiotos, K. (2015) · Journal of Pediatric Intensive Care · doi:10.3233/pic-14108 · Cited by 4
Are Echinocandins Better Than Azoles for Invasive Candidiasis?
Revankar, S. G., & Sobel, J. D. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0124-8 · Cited by 4
Metadata
- Authors
- Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M.
- Affiliations
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-14
- Volume
- 55
- Issue
- 10
- Pages
- 1352-1361
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2157512355
- Cited by
- 366
- References
- 138
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 17 · 2023: 16 · 2022: 23 · 2021: 32 · 2020: 35 · 2019: 21 · 2018: 42 · 2017: 35 · 2016: 28 · 2015: 44 · 2014: 33 · 2013: 19 · 2012: 2
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, candidemia incidence, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, multidrug resistance, infants, older adults, epidemiological trends, antifungal prophylaxis, infection control, catheter-related infection, Atlanta, Baltimore
- MeSH terms
- Adolescent, Adult, Aged, Antifungal Agents, Candida, Child, Child, Preschool, Female, Georgia, Humans, Infant, Male, Middle Aged, Population Surveillance, Prospective Studies, Baltimore, Incidence, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.